CXCR4 Receptor Modulators for HIV Entry and Metastasis Blocking
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for HIV and cancer are limited by the complexity of viral entry mechanisms and the role of CXCR4 co-receptors, and there is a need for effective CXCR4 antagonists to inhibit viral entry and metastasis.
Innovation Solution
Development of chemokine CXCR4 receptor modulators in the form of compounds represented by Formulas (I), (II), (III), and (IV), which can be administered alone or in combination with other active ingredients to target CXCR4 and inhibit its function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If compounds targeting viral entry are used, then HIV infection is inhibited, but the complexity of viral entry mechanisms makes drug design difficult
Solution Approach 1:
The patent extracts and targets a specific component (CXCR4 co-receptor) from the complex viral entry mechanism. By focusing on this single critical element rather than the entire multi-step entry process, the invention simplifies the therapeutic approach while maintaining effective HIV infection inhibition.
Solution Approach 2:
The patent segments the viral entry process into distinct targets: CD4 receptor, CCR5 co-receptor, and CXCR4 co-receptor. This segmentation allows for specialized compounds to target each component, making the overall complex mechanism manageable through focused intervention at multiple discrete points.
2Reliability
If CXCR4 antagonists are developed, then viral entry and metastasis are inhibited, but the need for combination therapy increases treatment complexity
Solution Approach 1:
The CXCR4 antagonist compounds described in the patent serve multiple functions: they inhibit HIV viral entry by blocking the CXCR4 co-receptor and also inhibit cancer metastasis by blocking the same receptor. This multi-functionality allows a single compound to address multiple disease processes, reducing the need for separate combination therapies.
3Reliability
If entry inhibitors are used, then HIV infection is blocked, but cross-resistance with other inhibitors may occur
Solution Approach 1:
Instead of targeting the viral components (gp120, gp41) as traditional entry inhibitors do, this patent inverts the approach by targeting the host cell components (CXCR4 co-receptor). This inversion creates a novel therapeutic mechanism that is unlikely to show cross-resistance with conventional viral-targeting inhibitors, as the target is fundamentally different.
Data Source
AI summary
The disclosure relates to chemokine CXCR4 receptor modulators and uses related thereto. The receptor modulators can be formulated to form pharmaceutical compositions comprising the disclosed compounds or pharmaceutically acceptable salts or prodrugs thereof. The compositions may be used for managing CXCR4 related conditions, typically prevention or treatment of viral infections abnormal cellular proliferation, retinal degeneration, inflammatory diseases, or as an immunostimulant or immunosuppressant or for managing cancer and may be administered with another active ingredient such as an antiviral agent or chemotherapeutic agent.